# Wolfgang A. Weber

Source: https://onco.cc/people/wolfgang-weber/  
OnCo record `wolfgang-weber` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nuclear medicine physician who established PET response criteria and leads Munich's radiopharmaceutical development pipeline.

## Summary

Wolfgang Weber led the early studies showing FDG-PET response after one cycle of chemotherapy predicts outcome in lung and gastro-oesophageal cancer and helped define PERCIST response criteria. He directs nuclear medicine at TUM, where PSMA ligands and FAP inhibitors were developed, and has been president of the Society of Nuclear Medicine and Molecular Imaging. His current focus is trial design for theranostics.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: nuclear-medicine; imaging; theranostics
- Role: Chair of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich
- Specialisms: Molecular imaging; PET response assessment; Theranostics; Radiopharmaceutical development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET

## Connected records

- technologies: [FAPI PET](https://onco.cc/technologies/fapi-pet/), [FDG PET](https://onco.cc/technologies/fdg-pet/), [PET (positron emission tomography)](https://onco.cc/technologies/pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- institutions: [Society of Nuclear Medicine and Molecular Imaging](https://onco.cc/institutions/snmmi/), [TUM Klinikum rechts der Isar / CCC München](https://onco.cc/institutions/tum-munich/)

---
JSON: https://onco.cc/api/v1/entities/wolfgang-weber.json